Open App
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Dr Reddys Laboratories

Dr Reddys Laboratories

BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Oct 04, 16:01
4412.00
-8.15 (-0.18%)
VOLUME 10,787
LIVE
NSE
Oct 04, 15:59
4413.95
-5.7 (-0.13%)
VOLUME 308,654
News on Dr Reddys Laboratories
Select Year: 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Trend likely to remain weak if Nifty remains below 17,000 mark

7.49 am | 29 Sep 2022 |  Source: Moneycontrol.com

The Nifty50 has witnessed significant amount of Call writing at higher levels and there has not been enough Put writing at the lower end to find a mea...

Buy Dr. Reddy’s Laboratories; target of Rs 4869: KR Choksey

3.34 pm | 31 Jul 2022 |  Source: Moneycontrol.com

KR Choksey is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 4869 in its research report date...

Buy Dr. Reddy's Laboratories; target of Rs 4750: Prabhudas Lilladher

3.26 pm | 31 Jul 2022 |  Source: Moneycontrol.com

Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4750 in its research ...

Buy Dr. Reddy’s Laboratories; target of Rs 5000: Sharekhan

2.39 pm | 31 Jul 2022 |  Source: Moneycontrol.com

Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5000 in its research report dated...

Buy Dr Reddy's Laboratories; target of Rs 4750: ICICI Direct

1.50 pm | 31 Jul 2022 |  Source: Moneycontrol.com

ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4750 in its research report d...

Dr Reddys Labs Consolidated June 2022 Net Sales at Rs 5,232.90 crore, up 5.82% Y-o-Y

10.22 pm | 28 Jul 2022 |  Source: Moneycontrol.com

NULL...

Dr Reddy’s Q1 Results Preview | Profit may rise 47-50%; revenue likely to grow 11-12%

8.22 pm | 27 Jul 2022 |  Source: Moneycontrol.com

During the current quarter, Dr Reddy’s stands to gain from the receipt of $72 million from the settlement of the Suboxone dispute with Indivior....

Buy Dr. Reddy’s Laboratories; target of Rs 5261: KR Choksey

1.46 pm | 24 May 2022 |  Source: Moneycontrol.com

KR Choksey is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5261 in its research report date...

Buy Dr Reddy's Laboratories; target of Rs 4800: ICICI Direct

8.49 pm | 21 May 2022 |  Source: Moneycontrol.com

ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4800 in its research report d...

Buy Dr. Reddy’s Laboratories: target of Rs 5550: Sharekhan

8.30 pm | 21 May 2022 |  Source: Moneycontrol.com

Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5550 in its research report dated...

Buy Dr Reddy’s Labs; target of Rs 4800: Motilal Oswal

7.52 pm | 21 May 2022 |  Source: Moneycontrol.com

Motilal Oswal is bullish on Dr Reddy’s Labs recommended buy rating on the stock with a target price of Rs 4800 in its research report dated May 20, ...

Dr Reddys Labs Consolidated March 2022 Net Sales at Rs 5,474.90 crore, up 14.82% Y-o-Y

4.00 pm | 19 May 2022 |  Source: Moneycontrol.com

NULL...

Dr Reddys Labs Standalone March 2022 Net Sales at Rs 3,668.70 crore, up 9.49% Y-o-Y

4.00 pm | 19 May 2022 |  Source: Moneycontrol.com

NULL...

Dr Reddy's Q4 consolidated net profit slumps 76% despite 15% rise in revenue

1.00 pm | 19 May 2022 |  Source: Moneycontrol.com

The pharmaceutical major reported a 15 percent year-on-year rise in consolidated revenues from operations...

Buy Dr. Reddy’s Laboratories: target of Rs 5550: Sharekhan

10.25 pm | 12 Apr 2022 |  Source: Moneycontrol.com

Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5550 in its research report dated...

Dr Reddy’s: Improving exposure to EMs adds to investment case

10.45 am | 04 Apr 2022 |  Source: Moneycontrol.com

Situation in Russia presents an opportunity for Indian pharma companies to gain market share in Russia...

1 2
Quick Links for Dr Reddys Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.